10-K Filing

TEVA PHARMACEUTICAL INDUSTRIES LTD CIK: 818686 FY 2017

Filing Information

Form Type	10-K
Accession Number	`0001193125-18-039076`
Period End Date	20171231
Filing Date	20180212
Fiscal Year	2017
Fiscal Period	FY
XBRL Instance	teva-20171231.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 79 Income Statement 106 Cash Flow Statement 142 Stockholders Equity 34 Comprehensive Income 27

Balance Sheet 79 line items

Line Item	Tag	Value	Unit	Period
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$2.23B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$6.95B	USD	Point-in-time
Cash and cash equivalents	`CashAndCashEquivalentsAtCarryingValue`	$963.00M	USD	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$7.52B	USD	Point-in-time
Trade receivables	`AccountsReceivableNetCurrent`	$7.13B	USD	Point-in-time
Inventories	`InventoryNet`	$4.95B	USD	Point-in-time
Inventories	`InventoryNet`	$4.92B	USD	Point-in-time
Assets Held For Sale	`AssetsHeldForSale`	$566.00M	USD	Point-in-time
Assets Held For Sale	`AssetsHeldForSale`	$841.00M	USD	Point-in-time
Prepaid Expenses	`PrepaidExpenses`	$1.10B	USD	Point-in-time
Prepaid Expenses	`PrepaidExpenses`	$1.63B	USD	Point-in-time
Other Current Assets	`OtherCurrentAssets`	$701.00M	USD	Point-in-time
Other Current Assets	`OtherCurrentAssets`	$1.29B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$17.23B	USD	Point-in-time
Total current assets	`AssetsCurrent`	$15.38B	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$932.00M	USD	Point-in-time
Other non-current assets	`OtherAssetsNoncurrent`	$1.24B	USD	Point-in-time
Deferred Income Taxes	`NonCurrentDeferredIncomeTaxes`	$625.00M	USD	Point-in-time
Deferred Income Taxes	`NonCurrentDeferredIncomeTaxes`	$574.00M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$7.67B	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$8.07B	USD	Point-in-time
Identifiable intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$21.49B	USD	Point-in-time
Identifiable intangible assets, net	`IntangibleAssetsNetExcludingGoodwill`	$17.64B	USD	Point-in-time
Goodwill	`Goodwill`	$44.41B	USD	Point-in-time
Goodwill	`Goodwill`	$19.02B	USD	Point-in-time
Goodwill	`Goodwill`	$28.41B	USD	Point-in-time
Total assets	`Assets`	$70.61B	USD	Point-in-time
Total assets	`Assets`	$93.06B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$3.65B	USD	Point-in-time
Short-term debt	`DebtCurrent`	$3.28B	USD	Point-in-time
Sales Reserves And Allowances	`SalesReservesAndAllowances`	$7.88B	USD	Point-in-time
Sales Reserves And Allowances	`SalesReservesAndAllowances`	$7.84B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.07B	USD	Point-in-time
Trade payables	`AccountsPayableAndAccruedLiabilitiesCurrent`	$2.16B	USD	Point-in-time
Employee Related Obligations	`EmployeeRelatedObligations`	$859.00M	USD	Point-in-time
Employee Related Obligations	`EmployeeRelatedObligations`	$549.00M	USD	Point-in-time
Accrued Expenses	`AccruedExpenses`	$3.01B	USD	Point-in-time
Accrued Expenses	`AccruedExpenses`	$3.40B	USD	Point-in-time
Liabilities Held For Sale	`LiabilitiesOfAssetsHeldForSales`	$116.00M	USD	Point-in-time
Liabilities Held For Sale	`LiabilitiesOfAssetsHeldForSales`	$38.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$836.00M	USD	Point-in-time
Other current liabilities	`OtherLiabilitiesCurrent`	$724.00M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$17.92B	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$18.49B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$5.41B	USD	Point-in-time
Deferred income taxes	`DeferredTaxLiabilitiesNoncurrent`	$3.28B	USD	Point-in-time
Other taxes and long term liabilities	`OtherLiabilitiesNoncurrent`	$1.64B	USD	Point-in-time
Other taxes and long term liabilities	`OtherLiabilitiesNoncurrent`	$1.84B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$32.52B	USD	Point-in-time
Senior notes and loans	`LongTermNotesAndLoans`	$28.83B	USD	Point-in-time
Total long term liabilities	`LiabilitiesNoncurrent`	$33.95B	USD	Point-in-time
Total long term liabilities	`LiabilitiesNoncurrent`	$39.58B	USD	Point-in-time
Total liabilities	`Liabilities`	$51.87B	USD	Point-in-time
Total liabilities	`Liabilities`	$58.06B	USD	Point-in-time
Preferred Shares	`PreferredStockValue`	$3.62B	USD	Point-in-time
Preferred Shares	`PreferredStockValue`	$3.63B	USD	Point-in-time
Ordinary shares	`CommonStockValue`	$54.00M	USD	Point-in-time
Ordinary shares	`CommonStockValue`	$54.00M	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.48B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapital`	$23.41B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$13.61B	USD	Point-in-time
Retained earnings	`RetainedEarningsAccumulatedDeficit`	$-3.80B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.34B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.85B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.96B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-3.16B	USD	Point-in-time
Treasury shares	`TreasuryStockValue`	$4.19B	USD	Point-in-time
Treasury shares	`TreasuryStockValue`	$4.15B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$17.36B	USD	Point-in-time
Stockholders' equity attributable to Teva shareholders	`StockholdersEquity`	$33.34B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.39B	USD	Point-in-time
Non-controlling interests	`MinorityInterest`	$1.66B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$23.36B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.93B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Total equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.99B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$93.06B	USD	Point-in-time
Total liabilities and equity	`LiabilitiesAndStockholdersEquity`	$70.61B	USD	Point-in-time

Income Statement 106 line items

Line Item	Tag	Value	Unit	Period
Net revenues	`SalesRevenueNet`	$6.49B	USD	1 Quarter
Net revenues	`SalesRevenueNet`	$4.81B	USD	1 Quarter
Net revenues	`SalesRevenueNet`	$5.04B	USD	1 Quarter
Net revenues	`SalesRevenueNet`	$5.46B	USD	1 Quarter
Net revenues	`SalesRevenueNet`	$5.72B	USD	1 Quarter
Net revenues	`SalesRevenueNet`	$5.65B	USD	1 Quarter
Net revenues	`SalesRevenueNet`	$5.56B	USD	1 Quarter
Net revenues	`SalesRevenueNet`	$21.90B	USD	Annual
Net revenues	`SalesRevenueNet`	$22.39B	USD	Annual
Net revenues	`SalesRevenueNet`	$5.61B	USD	1 Quarter
Net revenues	`SalesRevenueNet`	$19.65B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$11.56B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$8.30B	USD	Annual
Cost of sales	`CostOfGoodsAndServicesSold`	$10.04B	USD	Annual
Gross profit	`GrossProfit`	$11.36B	USD	Annual
Gross profit	`GrossProfit`	$3.39B	USD	1 Quarter
Gross profit	`GrossProfit`	$10.82B	USD	Annual
Gross profit	`GrossProfit`	$2.79B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.88B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.84B	USD	1 Quarter
Gross profit	`GrossProfit`	$11.86B	USD	Annual
Gross profit	`GrossProfit`	$2.80B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.54B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.64B	USD	1 Quarter
Gross profit	`GrossProfit`	$2.85B	USD	1 Quarter
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$1.85B	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$1.52B	USD	Annual
Research and development expenses	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$2.11B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$3.48B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$3.66B	USD	Annual
Selling and marketing expenses	`SellingAndMarketingExpense`	$3.86B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.36B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.33B	USD	Annual
General and administrative expenses	`GeneralAndAdministrativeExpense`	$1.28B	USD	Annual
Other Asset Impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$5.07B	USD	Annual
Other Asset Impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$1.42B	USD	Annual
Other Asset Impairments, restructuring and other items	`ImpairmentsRestructuringAndOthers`	$1.18B	USD	Annual
Legal Settlements And Loss Contingencies	`LegalSettlementsAndLossContingencies`	$500.00M	USD	Annual
Legal Settlements And Loss Contingencies	`LegalSettlementsAndLossContingencies`	$631.00M	USD	Annual
Legal Settlements And Loss Contingencies	`LegalSettlementsAndLossContingencies`	$899.00M	USD	Annual
Total Other Income	`OtherIncome`	$769.00M	USD	Annual
Total Other Income	`OtherIncome`	$166.00M	USD	Annual
Total Other Income	`OtherIncome`	$1.20B	USD	Annual
Goodwill Impairment	`GoodwillImpairmentLoss`	$17.10B	USD	Annual
Goodwill Impairment	`GoodwillImpairmentLoss`	-	USD	Annual
Goodwill Impairment	`GoodwillImpairmentLoss`	$11.00B	USD	1 Quarter
Goodwill Impairment	`GoodwillImpairmentLoss`	$6.10B	USD	1 Quarter
Goodwill Impairment	`GoodwillImpairmentLoss`	$900.00M	USD	Annual
Operating (loss) income	`OperatingIncomeLoss`	$2.15B	USD	Annual
Operating (loss) income	`OperatingIncomeLoss`	$-17.48B	USD	Annual
Operating (loss) income	`OperatingIncomeLoss`	$3.35B	USD	Annual
Financial expenses - net	`NonoperatingIncomeExpense`	$-895.00M	USD	Annual
Financial expenses - net	`NonoperatingIncomeExpense`	$-1.00B	USD	Annual
Financial expenses - net	`NonoperatingIncomeExpense`	$-1.33B	USD	Annual
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$2.35B	USD	Annual
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$-18.38B	USD	Annual
Income (loss) before income taxes	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments`	$824.00M	USD	Annual
Income taxes (Benefit)	`IncomeTaxExpenseBenefit`	$521.00M	USD	Annual
Income taxes (Benefit)	`IncomeTaxExpenseBenefit`	$634.00M	USD	Annual
Income taxes (Benefit)	`IncomeTaxExpenseBenefit`	$-1.93B	USD	Annual
Share in (profits) losses of associated companies net	`IncomeLossFromEquityMethodInvestments`	$-121.00M	USD	Annual
Share in (profits) losses of associated companies net	`IncomeLossFromEquityMethodInvestments`	$8.00M	USD	Annual
Share in (profits) losses of associated companies net	`IncomeLossFromEquityMethodInvestments`	$-3.00M	USD	Annual
Net income (loss)	`ProfitLoss`	$-16.45B	USD	Annual
Net income (loss)	`ProfitLoss`	$1.60B	USD	Annual
Net income (loss)	`ProfitLoss`	$311.00M	USD	Annual
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-184.00M	USD	Annual
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$9.00M	USD	Annual
Net income (loss) attributable to non-controlling interests	`NetIncomeLossAttributableToNoncontrollingInterest`	$-18.00M	USD	Annual
Net income (loss) attributable to Teva	`NetIncomeLoss`	$329.00M	USD	Annual
Net income (loss) attributable to Teva	`NetIncomeLoss`	$-16.27B	USD	Annual
Net income (loss) attributable to Teva	`NetIncomeLoss`	$1.59B	USD	Annual
Accrued dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$15.00M	USD	Annual
Accrued dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$261.00M	USD	Annual
Accrued dividends on preferred shares	`PreferredStockDividendsIncomeStatementImpact`	$260.00M	USD	Annual
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$68.00M	USD	Annual
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$-16.52B	USD	Annual
Net income (loss) attributable to ordinary shareholders	`NetIncomeLossAvailableToCommonStockholdersBasic`	$1.57B	USD	Annual
Basic	`EarningsPerShareBasic`	$-1.02	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.57	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.35	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-16.26	USD	Annual
Basic	`EarningsPerShareBasic`	$-11.41	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.62	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$-5.94	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$1.84	USD	Annual
Basic	`EarningsPerShareBasic`	$0.21	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.52	USD	1 Quarter
Basic	`EarningsPerShareBasic`	$0.07	USD	Annual
Diluted	`EarningsPerShareDiluted`	$0.52	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.57	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-16.26	USD	Annual
Diluted	`EarningsPerShareDiluted`	$0.07	USD	Annual
Diluted	`EarningsPerShareDiluted`	$0.62	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-11.41	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$1.82	USD	Annual
Diluted	`EarningsPerShareDiluted`	$0.20	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-1.02	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$-5.94	USD	1 Quarter
Diluted	`EarningsPerShareDiluted`	$0.35	USD	1 Quarter
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	855.00M	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	955.00M	shares	Annual
Basic	`WeightedAverageNumberOfSharesOutstandingBasic`	1.02B	shares	Annual
Diluted	`WeightedAverageNumberOfSharesOutstandingDiluted`	1.02B	shares	Annual
Diluted	`WeightedAverageNumberOfSharesOutstandingDiluted`	961.00M	shares	Annual
Diluted	`WeightedAverageNumberOfSharesOutstandingDiluted`	864.00M	shares	Annual

Cash Flow Statement 142 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-16.45B	USD	Annual
Net income (loss)	`ProfitLoss`	$1.60B	USD	Annual
Net income (loss)	`ProfitLoss`	$311.00M	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$2.11B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.31B	USD	Annual
Depreciation and amortization	`DepreciationAndAmortization`	$1.52B	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$363.00M	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$-1.22B	USD	Annual
Net change in operating assets and liabilities	`IncreaseDecreaseInOperatingCapital`	$-967.00M	USD	Annual
Deferred Income Taxes Net And Uncertain Tax Positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$237.00M	USD	Annual
Deferred Income Taxes Net And Uncertain Tax Positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$15.00M	USD	Annual
Deferred Income Taxes Net And Uncertain Tax Positions	`DeferredIncomeTaxesNetAndUncertainTaxPositions`	$-2.33B	USD	Annual
Venezuela Deconsolidation Loss	`DeconsolidationLoss`	$383.00M	USD	Annual
Venezuela Deconsolidation Loss	`DeconsolidationLoss`	-	USD	Annual
Venezuela Deconsolidation Loss	`DeconsolidationLoss`	-	USD	Annual
Research and development in process	`ResearchAndDevelopmentExpense`	$422.00M	USD	Annual
Research and development in process	`ResearchAndDevelopmentExpense`	$35.00M	USD	Annual
Research and development in process	`ResearchAndDevelopmentExpense`	$175.00M	USD	Annual
Venezuela impairment of net monetary assets	`VenezuelaImpairmentOfNetMonetaryAssets`	$603.00M	USD	Annual
Venezuela impairment of net monetary assets	`VenezuelaImpairmentOfNetMonetaryAssets`	$42.00M	USD	Annual
Impairment of long lived assets	`AssetImpairmentCharges`	$361.00M	USD	Annual
Impairment of long lived assets	`AssetImpairmentCharges`	$20.88B	USD	Annual
Impairment of long lived assets	`AssetImpairmentCharges`	$1.65B	USD	Annual
Impairment Of Equity Investment - Net	`ImpairmentOfInvestments`	-	USD	Annual
Impairment Of Equity Investment - Net	`ImpairmentOfInvestments`	$124.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$124.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$117.00M	USD	Annual
Stock-based compensation	`ShareBasedCompensation`	$133.00M	USD	Annual
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-146.00M	USD	Annual
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$14.00M	USD	Annual
Other items	`IncreaseDecreaseInOtherOperatingCapitalNet`	$-13.00M	USD	Annual
Other-than-temporary impairment	`GainFromRevaluationOfInvestments`	$-140.00M	USD	Annual
Other-than-temporary impairment	`GainFromRevaluationOfInvestments`	-	USD	Annual
Other-than-temporary impairment	`GainFromRevaluationOfInvestments`	$-736.00M	USD	Annual
Net (gain) loss from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$86.00M	USD	Annual
Net (gain) loss from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$764.00M	USD	Annual
Net (gain) loss from sale of long-lived assets and investments	`ProfitFromSaleOfLongLivedAssetsAndInvestment`	$1.09B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$5.54B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$5.22B	USD	Annual
Net cash provided by operating activities	`NetCashProvidedByUsedInOperatingActivities`	$3.51B	USD	Annual
Acquisitions of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$-43.00M	USD	Annual
Acquisitions of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$3.31B	USD	Annual
Acquisitions of businesses, net of cash acquired	`PaymentsToAcquireBusinessesNetOfCashAcquired`	$36.15B	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$874.00M	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$901.00M	USD	Annual
Purchases of property, plant and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$772.00M	USD	Annual
Purchases of investments and other assets	`PaymentToAquireMarketableSecuritiesAndOtherAssets`	$2.00B	USD	Annual
Purchases of investments and other assets	`PaymentToAquireMarketableSecuritiesAndOtherAssets`	$481.00M	USD	Annual
Purchases of investments and other assets	`PaymentToAquireMarketableSecuritiesAndOtherAssets`	$200.00M	USD	Annual
Proceeds from sales of long-lived assets and investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$524.00M	USD	Annual
Proceeds from sales of long-lived assets and investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$2.00B	USD	Annual
Proceeds from sales of long-lived assets and investments	`ProceedsFromSaleAndMaturityOfMarketableSecurities`	$3.48B	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$282.00M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$5.00M	USD	Annual
Other investing activities	`PaymentsForProceedsFromOtherInvestingActivities`	$212.00M	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$2.16B	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-35.74B	USD	Annual
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-5.57B	USD	Annual
Proceeds from issuance of ordinary shares, net of issuance costs	`ProceedsFromIssuanceOfCommonStock`	$3.29B	USD	Annual
Proceeds from issuance of ordinary shares, net of issuance costs	`ProceedsFromIssuanceOfCommonStock`	$329.00M	USD	Annual
Proceeds from issuance of ordinary shares, net of issuance costs	`ProceedsFromIssuanceOfCommonStock`	-	USD	Annual
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	$329.00M	USD	Point-in-time
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	-	USD	Annual
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	$329.00M	USD	Annual
Proceeds from issuance of mandatory convertible preferred shares, net of issuance costs	`ProceedsFromIssuanceOfPreferredStockAndPreferenceStock`	$3.29B	USD	Annual
Purchase of treasury shares	`PaymentsForRepurchaseOfCommonStock`	-	USD	Annual
Purchase of treasury shares	`PaymentsForRepurchaseOfCommonStock`	$439.00M	USD	Annual
Purchase of treasury shares	`PaymentsForRepurchaseOfCommonStock`	-	USD	Annual
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$29.00M	USD	Annual
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$-1.68B	USD	Annual
Net change in short-term debt	`ProceedsFromRepaymentsOfShortTermDebt`	$2.00B	USD	Annual
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$1.16B	USD	Annual
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$1.30B	USD	Annual
Dividends paid on ordinary shares	`PaymentsOfDividendsCommonStock`	$901.00M	USD	Annual
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStock`	-	USD	Annual
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStock`	$260.00M	USD	Annual
Dividends paid on preferred shares	`PaymentsOfDividendsPreferredStock`	$255.00M	USD	Annual
Dividends Paid To Non Controlling Interest	`PaymentsOfDividendsToNonControllingInterest`	-	USD	Annual
Dividends Paid To Non Controlling Interest	`PaymentsOfDividendsToNonControllingInterest`	$38.00M	USD	Annual
Dividends Paid To Non Controlling Interest	`PaymentsOfDividendsToNonControllingInterest`	-	USD	Annual
Proceeds from exercise of options by employees	`ProceedsFromStockOptionsExercised`	$388.00M	USD	Annual
Proceeds from exercise of options by employees	`ProceedsFromStockOptionsExercised`	$35.00M	USD	Annual
Proceeds from exercise of options by employees	`ProceedsFromStockOptionsExercised`	-	USD	Annual
Proceeds from long-term loans and other long-term liabilities, net of issuance costs	`ProceedsFromLongTermLoansAndOtherLongTermLiabilities`	$506.00M	USD	Annual
Proceeds from long-term loans and other long-term liabilities, net of issuance costs	`ProceedsFromLongTermLoansAndOtherLongTermLiabilities`	$25.25B	USD	Annual
Proceeds from long-term loans and other long-term liabilities, net of issuance costs	`ProceedsFromLongTermLoansAndOtherLongTermLiabilities`	$2.10B	USD	Annual
Repayment of long-term loans And Other Long Term Liabilities	`RepaymentsOfLongTermDebt`	$2.52B	USD	Annual
Repayment of long-term loans And Other Long Term Liabilities	`RepaymentsOfLongTermDebt`	$999.00M	USD	Annual
Repayment of long-term loans And Other Long Term Liabilities	`RepaymentsOfLongTermDebt`	$3.30B	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-169.00M	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-178.00M	USD	Annual
Other financing activities	`ProceedsFromPaymentsForOtherFinancingActivities`	$-74.00M	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$4.80B	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$25.22B	USD	Annual
Net cash provided by (used in) financing activities	`NetCashProvidedByUsedInFinancingActivities`	$-5.75B	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-660.00M	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$-62.00M	USD	Annual
Translation adjustment on cash and cash equivalents	`EffectOfExchangeRateOnCashAndCashEquivalents`	$54.00M	USD	Annual
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-25.00M	USD	Annual
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$-5.96B	USD	Annual
Net change in cash and cash equivalents	`CashAndCashEquivalentsPeriodIncreaseDecrease`	$4.72B	USD	Annual
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$2.23B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$6.95B	USD	Point-in-time
Balance of cash and cash equivalents at beginning of period	`CashAndCashEquivalentsAtCarryingValue`	$963.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$988.00M	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$2.23B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$6.95B	USD	Point-in-time
Balance of cash and cash equivalents at end of period	`CashAndCashEquivalentsAtCarryingValue`	$963.00M	USD	Point-in-time
Cash paid during the year for Interest	`InterestPaid`	$243.00M	USD	Annual
Cash paid during the year for Interest	`InterestPaid`	$290.00M	USD	Annual
Cash paid during the year for Interest	`InterestPaid`	$795.00M	USD	Annual
Cash paid during the year for Income taxes, net of refunds	`IncomeTaxesPaidNet`	$341.00M	USD	Annual
Cash paid during the year for Income taxes, net of refunds	`IncomeTaxesPaidNet`	$802.00M	USD	Annual
Cash paid during the year for Income taxes, net of refunds	`IncomeTaxesPaidNet`	$106.00M	USD	Annual
Shares Issuance To Allergan plc for the Actavis Generics acquisition	`SharesIssuedToPurchaseActavisGenerics`	-	USD	Point-in-time
Shares Issuance To Allergan plc for the Actavis Generics acquisition	`SharesIssuedToPurchaseActavisGenerics`	-	USD	Point-in-time
Shares Issuance To Allergan plc for the Actavis Generics acquisition	`SharesIssuedToPurchaseActavisGenerics`	$5.07B	USD	Point-in-time
Shares Transferred To Takeda As Part Of The Establishment Of Teva Takeda	`SharesTransferredToTakeda`	-	USD	Point-in-time
Shares Transferred To Takeda As Part Of The Establishment Of Teva Takeda	`SharesTransferredToTakeda`	-	USD	Point-in-time
Shares Transferred To Takeda As Part Of The Establishment Of Teva Takeda	`SharesTransferredToTakeda`	$1.82B	USD	Point-in-time
Actavis Generics Contingent Consideration	`ActavisContingentConsideration`	$302.00M	USD	Point-in-time
Actavis Generics Contingent Consideration	`ActavisContingentConsideration`	-	USD	Point-in-time
Actavis Generics Contingent Consideration	`ActavisContingentConsideration`	-	USD	Point-in-time
Trade Receivable	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$343.00M	USD	Annual
Trade Receivable	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$763.00M	USD	Annual
Trade Receivable	`IncreaseDecreaseInCertainCurrentAssetsExcludingInventories`	$514.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$372.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$129.00M	USD	Annual
Inventories	`IncreaseDecreaseInInventories`	$199.00M	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$87.00M	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$-517.00M	USD	Annual
Other current assets	`IncreaseDecreaseInOtherCurrentAssets`	$658.00M	USD	Annual
Trade payable accrued expenses employee related obligations and other current liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$640.00M	USD	Annual
Trade payable accrued expenses employee related obligations and other current liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$-1.80B	USD	Annual
Trade payable accrued expenses employee related obligations and other current liabilities	`IncreaseDecreaseInCertainCurrentLiabilitiesExcludingDebt`	$-12.00M	USD	Annual
Inventory Step Up	`InventoryStepUp`	$67.00M	USD	Annual
Inventory Step Up	`InventoryStepUp`	$381.00M	USD	Annual
Inventory Step Up	`InventoryStepUp`	-	USD	Annual
Net change in operating assets and liabilities	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$967.00M	USD	Annual
Net change in operating assets and liabilities	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$-363.00M	USD	Annual
Net change in operating assets and liabilities	`NetChangeInItemsComprisingSupplementalDisclosureOfCashFlowInformation`	$1.22B	USD	Annual

Stockholders Equity 34 line items

Line Item	Tag	Value	Unit	Period
Exercise Of Options By Employees And Vested RSUs	`StockIssuedDuringPeriodValueStockOptionsExercised`	$35.00M	USD	Annual
Exercise Of Options By Employees And Vested RSUs	`StockIssuedDuringPeriodValueStockOptionsExercised`	$388.00M	USD	Annual
Exercise Of Options By Employees And Vested RSUs	`StockIssuedDuringPeriodValueStockOptionsExercised`	-	USD	Annual
Ordinary shares issuance value	`StockIssuedDuringPeriodValueNewIssues`	$5.39B	USD	Annual
Ordinary shares issuance	`StockIssuedDuringPeriodSharesNewIssues`	3.29B	shares	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$117.00M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$133.00M	USD	Annual
Stock-based compensation expense	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$159.00M	USD	Annual
Dividends To Ordinary Shareholders	`DividendsCommonStockCash`	$1.30B	USD	Annual
Dividends To Ordinary Shareholders	`DividendsCommonStockCash`	$901.00M	USD	Annual
Dividends To Ordinary Shareholders	`DividendsCommonStockCash`	$1.16B	USD	Annual
Purchase of treasury shares	`StockIssuedDuringPeriodValueTreasuryStockReissued`	$439.00M	USD	Annual
Mcps Issuance	`MandatoryconvertiblePreferredSharesIssuedDuringPeriodSharesNewIssues`	$3.29B	USD	Point-in-time
Mcps Issuance	`MandatoryconvertiblePreferredSharesIssuedDuringPeriodSharesNewIssues`	$329.00M	USD	Point-in-time
Accrued Dividends to preferred shareholders	`DividendsPreferredStockCash`	$-261.00M	USD	Annual
Accrued Dividends to preferred shareholders	`DividendsPreferredStockCash`	$-15.00M	USD	Annual
Acquisition of non-controlling interests	`MinorityInterestDecreaseFromRedemptions`	$1.68B	USD	Annual
Other	`OtherEquity`	$-15.00M	USD	Point-in-time
Other	`OtherEquity`	$7.00M	USD	Point-in-time
Other	`OtherEquity`	$-40.00M	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$23.36B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.93B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.99B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$23.36B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$29.93B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$18.75B	USD	Point-in-time
Balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$34.99B	USD	Point-in-time
Total Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$-953.00M	USD	Annual
Total Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$984.00M	USD	Annual
Total Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$-15.08B	USD	Annual
Dividends To Preferred Shareholders	`DividendsToPreferredShareholders`	$-249.00M	USD	Annual
Disposition Of Non Controlling Interests	`DispositionOfNonControllingInterests`	$103.00M	USD	Annual
Transactions With Non Controlling Interests	`TransactionsWithNonControllingInterests`	$-111.00M	USD	Annual

Comprehensive Income 27 line items

Line Item	Tag	Value	Unit	Period
Net income (loss)	`ProfitLoss`	$-16.45B	USD	Annual
Net income (loss)	`ProfitLoss`	$1.60B	USD	Annual
Net income (loss)	`ProfitLoss`	$311.00M	USD	Annual
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$1.52B	USD	Annual
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-1.10B	USD	Annual
Currency translation adjustment	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-445.00M	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$477.00M	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$-135.00M	USD	Annual
Unrealized gain (loss) on derivative financial instruments, net	`OtherComprehensiveIncomeUnrealizedGainLossOnDerivativesArisingDuringPeriodTax`	$140.00M	USD	Annual
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$319.00M	USD	Annual
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$3.00M	USD	Annual
Unrealized gain (loss) on available-for-sale securities, net	`OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax`	$-319.00M	USD	Annual
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-23.00M	USD	Annual
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$35.00M	USD	Annual
Unrealized gain (loss) on defined benefit plans	`OtherComprehensiveIncomeLossFinalizationOfPensionAndNonPensionPostretirementPlanValuationNetOfTax`	$-10.00M	USD	Annual
Total Other Comprehensive Income (Loss)	`TotalOtherComprehensiveIncomeLoss`	$1.26B	USD	Annual
Total Other Comprehensive Income (Loss)	`TotalOtherComprehensiveIncomeLoss`	$613.00M	USD	Annual
Total Other Comprehensive Income (Loss)	`TotalOtherComprehensiveIncomeLoss`	$-1.37B	USD	Annual
Total Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$-953.00M	USD	Annual
Total Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$984.00M	USD	Annual
Total Comprehensive Income (loss)	`ComprehensiveIncomeNetOfTax`	$-15.08B	USD	Annual
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveLossAttributableToNonControllingInterests`	$-121.00M	USD	Annual
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveLossAttributableToNonControllingInterests`	$8.00M	USD	Annual
Comprehensive income (loss) attributable to non-controlling interests	`ComprehensiveLossAttributableToNonControllingInterests`	$-78.00M	USD	Annual
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-14.96B	USD	Annual
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$976.00M	USD	Annual
Comprehensive income (loss) attributable to Teva	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-875.00M	USD	Annual

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.